未经证实:采用直接抗病毒药物(DAA)治疗丙型肝炎病毒(HCV)克服了以干扰素为基础的治疗的许多缺点。DAA实现了持续的病毒应答(SVR)率超过90%,并克服了聚乙二醇化干扰素方案的许多缺点。HCV基因型(GT)分布因地理区域而异,GT-4在中东地区最普遍,包括沙特阿拉伯。然而,关于在沙特人口中使用DAA的现实证据是有限的。因此,这项研究的目的是调查DAAs在沙特阿拉伯HCV感染患者中的有效性和安全性。
UNASSIGNED:一项回顾性队列研究包括2015年至2017年在利雅得一家三级医院接受DAA治疗的患者,沙特阿拉伯。包括所有接受ledipasvir加索非布韦(LDS/SOF)±利巴韦林(RBV)或ombitasvir-paritaprevir-ritonavir(OBV/PTV/r)±dasabuvir(DSV)±RBV治疗的HCV患者。使用符合协议的分析,有效性结局是治疗结束应答(EOTr)和竞争方案后12周的持续病毒学应答(SVR12).次要安全性结果是患者报告的与治疗相关的不良事件。
未经证实:共纳入97例患者,其中大多数感染了GT-4(64%),其次是GT-1(18%),除了8%具有混合GT(1+4)。EOTr和SVR12率分别为98%和96%,分别。SVR12在LDS/SOF±RBV组中为94.4%,在OBV/PTV/r±DSV±RBV组中为97.7%。只有4%的人因复发或突破而反应失败,均感染混合GT1+4。药物耐受性良好,副作用最小,包括呕吐,恶心,和弱点。
UASSIGNED:DAA方案与SVR12的高发生率相关,并且在沙特HCV感染患者中具有良好的耐受性和良好的安全性。
UNASSIGNED: The introduction of direct-acting antivirals (DAA) to treat the hepatitis C virus (HCV) overcame many drawbacks of interferon-based therapy. DAA achieved sustained viral response (SVR) rates above 90% and overcame many drawbacks of pegylated interferon regimens.The HCV genotype (GT) distribution varies by geographical area, with GT-4 being most prevalent in the Middle East region, including Saudi Arabia. Yet, the real-world evidence about using DAAs in the Saudi population is limited.Thus, the aim of this study to investigate the effectiveness and safety of DAAs in Saudi patients with HCV infection.
UNASSIGNED: A retrospective cohort study included patients treated with DAAs from 2015 to 2017 at a tertiary care hospital in Riyadh, Saudi Arabia. All patients with HCV treated with either ledipasvir plus sofosbuvir (LDS/SOF) ± ribavarin (RBV) or ombitasvir-paritaprevir-ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± RBV were included. Using a per-protocol analysis, the effectiveness outcome was the end-of-treatment response (EOTr) and Sustained virologic reponce12 weeks after competing the regimen (SVR12). The secondary safety outcome was the adverse event related to the therapy reported by the patients.
UNASSIGNED: A total of 97 patients were included; with the majority infected with GT-4 (64 %), followed by GT-1 (18 %), in addition to 8 % having a mixed GT (1 + 4). The EOTr and SVR12 rates were 98 % and 96 %, respectively. SVR12 was 94.4 % within the LDS/SOF ± RBV group and 97.7 % within the OBV/PTV/r ± DSV ± RBV group. Only 4 % had a response failure due to relapse or breakthrough, and all were infected with mixed GT1 + 4. Medications were well tolerated with minimal side effects, including vomiting, nausea, and weakness.
UNASSIGNED: DAAs regimens are associated with high rates of SVR12 and are well tolerated with a good safety profile in Saudi HCV-infected patients.